Laidlaw initiated coverage on Lifeward with a new price target
$LFWD
Industrial Specialties
Health Care
Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $10.00 | Buy | Laidlaw |
4 - Lifeward Ltd. (0001607962) (Issuer)
4 - Lifeward Ltd. (0001607962) (Issuer)
4 - Lifeward Ltd. (0001607962) (Issuer)
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that effective with the open of the market on February 24, 2026, the Company will complete a 1-for-12 reverse split of its ordinary shares. On January 6, 2026, the Company's shareholders voted to authorize the Company's Board of Directors to determine whether to effect a reverse share split of the Company's ordinary shares and, if so, to set a ratio to be effective on a date to be determined by the Board. The
Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton Together, these three national Medicare Advantage insurers represent approximately 16 million beneficiaries across the United States HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that Aetna has issued a prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Pers
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical programOramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrantsMark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platformsIn addition, strategic investment by Oramed designed to bring Lifeward towards profitabilityLifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quartersNE
8-K - Lifeward Ltd. (0001607962) (Filer)
DEFM14A - Lifeward Ltd. (0001607962) (Filer)
8-K - Lifeward Ltd. (0001607962) (Filer)
Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00
4 - Lifeward Ltd. (0001607962) (Issuer)
4 - Lifeward Ltd. (0001607962) (Issuer)
4 - Lifeward Ltd. (0001607962) (Issuer)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. "On behalf of the Board and entire Lifeward team, I congratulate Joe on his appointment as Chief Executive Officer of Care Enablement at Fresenius Medical Care, a global leader
Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administrati
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia
Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and nine months ended September 3
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its third quarter 2025 financial results before the markets open on Friday, November 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561Inte
Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments for Lifeward Achieve